Target intelligence / Profile preview

Cytoplasmic dynein 2 intermediate chain 2 (DYNC2I2)

Target
DYNC2I2
Molecular classification
WD repeat protein family, motor protein accessory subunit, intraflagellar transport complex component
01

Overview

Cytoplasmic dynein 2 intermediate chain 2 (DYNC2I2, also known as WDR34) is a non-catalytic accessory subunit of the cytoplasmic dynein-2 complex, which is a motor protein complex critical for retrograde intraflagellar transport (IFT)—the movement of protein and molecular cargoes from the tip to the base of cilia and flagella, essential for normal ciliogenesis and ciliary signaling. It belongs to the WD repeat protein family, facilitating multiprotein complex formation and interaction. The dynein-2 complex contains two heavy chains, each partnering with either WDR34 (DYNC2I2) or WDR60, forming a heterodimer needed for proper dynein-2 function and cilia assembly. DYNC2I2 is involved in maintaining the transition zone in cilia, and defects in this gene cause short-rib thoracic dysplasia 11 with or without polydactyly. It can also act as a modulator of inflammation by negatively regulating the NF-κB pathway through inhibition of MAP3K7-induced signaling[1][4][3][5]. No clinically approved drugs directly target DYNC2I2; it functions primarily in structural and transport roles and is not currently considered a direct therapeutic target.

Other names
WDR34DIC5MGC20486bA216B9.3FAP133CFAP133SRTD11WD repeat-containing protein 34WD repeat domain 34Dynein 2 intermediate chain 2
02

Biological functions

Retrograde intraflagellar transport (IFT) in cilia and flagellaCiliogenesisRegulation of ciliary protein traffickingMaintenance of functional transition zone in the ciliumNegative regulator of Toll-like and IL-1 receptor signaling pathways (inhibits NF-κB activation)
03

Disease associations

Short-rib thoracic dysplasia 11 with or without polydactylyCiliopathies (general)
04

Safety considerations

Dysfunction may lead to developmental skeletal disorders and ciliary dysfunction disordersKey implications in ciliopathy pathogenesis[4][3]

Beyond the preview

Go deeper on Cytoplasmic dynein 2 intermediate chain 2 (DYNC2I2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytoplasmic dynein 2 intermediate chain 2 (DYNC2I2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call